GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Enovis Corp (NYSE:ENOV) » Definitions » Sloan Ratio %

Enovis (Enovis) Sloan Ratio % : 1.65% (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Enovis Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Enovis's Sloan Ratio for the quarter that ended in Dec. 2023 was 1.65%.

As of Dec. 2023, Enovis has a Sloan Ratio of 1.65%, indicating the company is in the safe zone and there is no funny business with accruals.


Enovis Sloan Ratio % Historical Data

The historical data trend for Enovis's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enovis Sloan Ratio % Chart

Enovis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.19 -1.15 0.42 5.12 1.65

Enovis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.12 3.67 2.35 2.61 1.65

Competitive Comparison of Enovis's Sloan Ratio %

For the Specialty Industrial Machinery subindustry, Enovis's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enovis's Sloan Ratio % Distribution in the Industrial Products Industry

For the Industrial Products industry and Industrials sector, Enovis's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Enovis's Sloan Ratio % falls into.



Enovis Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Enovis's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-33.261-134.988
--242.467)/4509.334
=1.65%

Enovis's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-33.261-134.988
--242.467)/4509.334
=1.65%

Enovis's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -23.35 (Mar. 2023 ) + -9.995 (Jun. 2023 ) + -2.88 (Sep. 2023 ) + 2.964 (Dec. 2023 ) = $-33 Mil.
Enovis's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 7.457 (Mar. 2023 ) + 28.103 (Jun. 2023 ) + 31.013 (Sep. 2023 ) + 68.415 (Dec. 2023 ) = $135 Mil.
Enovis's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -34.385 (Mar. 2023 ) + -131.603 (Jun. 2023 ) + -17.107 (Sep. 2023 ) + -59.372 (Dec. 2023 ) = $-242 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enovis  (NYSE:ENOV) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Enovis has a Sloan Ratio of 1.65%, indicating the company is in the safe zone and there is no funny business with accruals.


Enovis Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Enovis's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Enovis (Enovis) Business Description

Traded in Other Exchanges
Address
2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808
Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy.. The company conducts its operations through two operating segments: Prevention & Recovery ("P&R") and Reconstructive ("Recon"). It generates majority revenue form Prevention & Recovery segment.
Executives
John Kleckner officer: Principal Accounting Officer 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Berry Phillip Benjamin (ben) officer: SVP, Chief Financial Officer 2711 CENTERVILLE ROAD SUITE 400, WILMINGTON DE 19808
Rajiv Vinnakota director 8730 STONY POINT PARKWAY, SUITE 150, RICHMOND VA 23235
A Clayton Perfall director
Brady Shirley officer: EVP, Colfax, Pres. & CEO, DJO 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Patricia A Lang officer: SVP, Chief HR Officer C/O DIEBOLD NIXDORF, INCORPORATED, 5995 MAYFAIR ROAD, NORTH CANTON OH 44720
Bradley J Tandy officer: SVP, General Counsel P.O. BOX 587, 56 E. BELL DRIVE, WARSAW IN 46580
Daniel A Pryor officer: SVP??Strategy & Business Deve. DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Matthew L. Trerotola director, officer: President & CEO 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Christopher M Hix officer: SVP, Chief Financial Officer 2160 SATELLITE BLVD., SUITE 200, DULUTH GA 30097
Barbara W. Bodem director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Christine Ortiz director 1200 ABERNATHY ROAD, NE, SUITE 1200, ATLANTA GA 30328
Angela S Lalor director 3M CENTER, BLDG. 0220-09-E-02, ST PAUL MN 55144 1000
Shyam Kambeyanda officer: ESAB President and SVP, Colfax 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Douglas J. Pitts officer: Controller, PAO 100 MATSONFORD ROAD, RADNOR PA 19087